NCT01184482View on ClinicalTrials.gov

Lapatinib and Cetuximab in Patients With Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

June 30, 2010

Primary Completion Date

June 30, 2013

Study Completion Date

September 30, 2013

Conditions
Colorectal CancerLung CancerHead and Neck Cancer
Interventions
DRUG

cetuximab and lapatinib

"Cetuximab: 400 mg/m2 on Day 1 then 250 mg/m2 weekly~Lapatinib: Start once daily on Day 1. Dose escalating cohorts:~1. 750 mg (3 tabs)~2. 1000 mg (4 tabs)~3. 1250 mg (5 tabs)"

Trial Locations (1)

20007

Georgetown University Medical Center, Washington D.C.

Sponsors

Collaborators (1)

GlaxoSmithKline
All Listed Sponsors
collaborator

GlaxoSmithKline

INDUSTRY

lead

Georgetown University

OTHER

NCT01184482 - Lapatinib and Cetuximab in Patients With Solid Tumors | Biotech Hunter | Biotech Hunter